Smart Opinion
Smart Opinion is a Japanese company focused on revolutionizing breast cancer screening. They have developed an AI-powered ultrasound examination system called 'Smaopi', which utilizes their proprietary AI technology 'METIS Eye'. This system, developed over seven years in collaboration with Keio University Hospital, received pharmaceutical approval as a medical device program in May 2024. Smaopi aims to improve the accuracy and accessibility of breast cancer screening by combining AI analysis with human review, addressing limitations of mammography, especially for dense breasts, and the variability in human interpretation of ultrasound images. The company's mission is to make early breast cancer detection a norm and create a world where breast cancer is not feared.
Smart Opinion
Smart Opinion is a Japanese company focused on revolutionizing breast cancer screening. They have developed an AI-powered ultrasound examination system called 'Smaopi', which utilizes their proprietary AI technology 'METIS Eye'. This system, developed over seven years in collaboration with Keio University Hospital, received pharmaceutical approval as a medical device program in May 2024. Smaopi aims to improve the accuracy and accessibility of breast cancer screening by combining AI analysis with human review, addressing limitations of mammography, especially for dense breasts, and the variability in human interpretation of ultrasound images. The company's mission is to make early breast cancer detection a norm and create a world where breast cancer is not feared.